Legal
Filter News
Found 9,768 articles
-
The proposed drug pricing legislations follow the Inflation Reduction Act, passed in August 2022. -
TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab
4/25/2023
TRACON Pharmaceuticals, Inc. today announced that the tribunal in the arbitration against I-Mab conducted under the Rules of Arbitration of the International Chamber of Commerce (ICC) rendered an award to TRACON in the aggregate amount of approximately $23.0 million.
-
Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration
4/25/2023
Alkermes plc (Nasdaq: ALKS) today announced that on April 19, 2023 it received a second interim award (the "Second Interim Award") from the arbitral tribunal (the "Tribunal") in its arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V.
-
Friday, the Supreme Court granted the FDA’s application for a stay, effectively maintaining access to the abortion pill mifepristone as its case goes through the appeals process. -
Defence Granted US Patent with Broad Coverage on Accum(TM)-based Vaccine Enhancer Platform Technology
4/24/2023
Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugates ("ADCs"), is pleased to announce the issuance of its US patent no. 11,612,651 by the United States Patent and Trademark Office (USPTO).
-
The Supreme Court extended the stay deadline to Friday at midnight to keep mifepristone on the market in the interim without conditions.
-
The lawsuit, brought by Arbutus Biopharma, marks the latest legal action in an ongoing battle for intellectual property underlying mRNA vaccines for COVID-19.
-
In an open letter published Monday, more than 480 biopharma industry leaders expressed their support for the FDA after a Texas federal judge ruled to hold the approval of the abortion pill mifepristone.
-
A California judge denied Elizabeth Holmes’ motion for release pending appeal, ruling that the former Theranos CEO must serve her prison sentence while she appeals her guilty verdict.
-
Farallon Capital Management is waging a proxy battle with Exelixis over R&D spending. The hedge fund issued a letter to the company’s board of directors on Wednesday.
-
NLRB General Counsel Jennifer Abruzzo issued a memo to all field offices clarifying the board’s recent ruling in a case regarding severance agreements. -
A federal court sided in favor of Vanda Pharmaceuticals in its Freedom of Information Act case against the FDA regarding the CRL for its sleep drug label expansion.
-
Citing reports of “alarming toxicity” among other accusations, short-seller Scorpion Capital will file a Citizen’s Petition with the FDA to have its approval of Wakix withdrawn.
-
CytoDyn has spent the past two years under siege. In an exclusive interview, Cyrus Arman, president, told BioSpace how the company is looking to turn the page.
-
Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences
3/14/2023
Mindset Pharma Inc. today announced that the Company has been made aware that Reunion Neuroscience Inc. (“Reunion”) has filed a lawsuit against Mindset in the United States District Court for the District of New Jersey asserting, among others, inventorship and co-ownership of one of Mindset’s patents, inequitable conduct, and breach of contract.
-
Treace Medical Announces Settlement of Lawsuit Again Fusion Orthopedics
3/3/2023
Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) jointly announces with Fusion Orthopedics, LLC (“Fusion Orthopedics”) that they have reached an amicable resolution of the litigation between the parties.
-
Senate Bill 1162, a law requiring employers to include pay ranges in all job advertisements, went into effect in California January 1. Here's how employers are responding.
-
Xlear Provides New Data to the Dept. Of Justice; Study Showing Nasal Spray Reduces COVID-19 Infections by 62% Included
2/27/2023
Xlear has supplemented the numerous scientific studies it has already provided the Department of Justice and the Federal Trade Commission (FTC) in the government’s lawsuit against Xlear.
-
The Pregnant Workers Fairness Act (PWFA) has been praised by many in the life sciences who see it as a step forward in protecting the rights of pregnant employees.
-
Trade secrets litigations and disputes have been on the rise in recent years, and given the FTC's recent proposal to ban all non-compete agreements nationwide, the trend is likely to continue.